An update of the blockade of the renin angiotensin aldosterone system in clinical practice

A possible mechanism for the progression of chronic renal disease and congestive heart failure

(2015) Richard N. Re   Journal of the American Society of Hypertension

Novel RAAS agonists and antagonists: clinical applications and controversies

(2015) Cesar A. Romero et al.   Nature Reviews Endocrinology

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

(2015) Matthew R. Weir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

(2014) Kazuomi Kario et al.   HYPERTENSION

Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia

(2014) Mikhail Kosiborod et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Does cardiovascular protection translate into renal protection?

(2014) Gema Ruiz-Hurtado et al.   Nature Reviews Cardiology

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Agents That Affect Aldosterone Action

(2014) Juan Tamargo et al.   SEMINARS IN NEPHROLOGY

Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease

(2014) Ivana Lazich et al.   SEMINARS IN NEPHROLOGY

2013 ESH/ESC Guidelines for the management of arterial hypertension

(2013)   EUROPEAN HEART JOURNAL

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

(2013) Bertram Pitt et al.   EUROPEAN HEART JOURNAL

Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition

(2013) Julian Segura et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults

(2013) Paul A. James et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistant Hypertension and Aldosterone: An Update

(2012) Donald Clark et al.   CANADIAN JOURNAL OF CARDIOLOGY

Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics

(2012) Sarah Mangiafico et al.   EUROPEAN HEART JOURNAL

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC

(2012) et al.   EUROPEAN HEART JOURNAL

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

(2012) F. Zannad et al.   EUROPEAN HEART JOURNAL

New drugs, procedures, and devices for hypertension

(2012) Stéphane Laurent et al.   LANCET

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

(2012) Scott D Solomon et al.   LANCET

A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Stephen S Lim et al.   LANCET

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

(2012) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

(2011) Matthew J. Volk et al.   CURRENT HYPERTENSION REPORTS

Renal function and target organ damage in hypertension

(2011) L. M. Ruilope et al.   EUROPEAN HEART JOURNAL

Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial

(2011) B. Pitt et al.   EUROPEAN HEART JOURNAL

Validation of a therapeutic scheme for the treatment of resistant hypertension

(2011) Julian Segura et al.   Journal of the American Society of Hypertension

Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease

(2011) R. E. Schmieder et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics

(2011) Peter Kolkhof et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Current challenges in the clinical management of hypertension

(2011) Luis M. Ruilope   Nature Reviews Cardiology

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

(2010) George L Bakris et al.   LANCET

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study

(2009) Peter Sleight et al.   JOURNAL OF HYPERTENSION

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE